Skip to main content
SpringerLink
Log in

Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Gonadotropin releasing hormone (GnRH) agonists have shown to be effective in the treatment of several sex-hormone-dependent conditions. However, their use could be limited by the bone loss they induce. To evaluate the use of nasal salmon calcitonin (sCT) in preventing this bone loss, 40 patients with endometriosis were treated for 6 months with triptoreline (3.75 mg monthly) and calcium (1 g daily), and randomized in three groups — placebo, sCT 100 IU daily and sCT 200 IU daily — in a prospective double-masked study. Dual-energy X-ray absorptiometry and biochemical parameters were used to evaluate the benefit of the treatment. At baseline, there were no statistically significant differences between the groups. After 6 months, estradiol and biochemical markers of bone metabolism were at postmenopausal levels, with no difference between the groups. There was no difference in bone loss in the three groups, at all sites. Mean lumbar bone loss was 4.01±2.59% (mean±SD) in this population. In this study dosages of 100 IU and 200 IU daily of nasal sCT were insufficient to prevent bone loss during GnRH agonist treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sandow J. Clinical applications of LHRH and its analogues. Clin Endocrinol 1983;18:571–86.

    Google Scholar 

  2. Shaw RW. Treatment of endometriosis. Lancet 1992;340:1267–71.

    Google Scholar 

  3. Gudmundsson JA, Ljunghall S, Bergquist C, Wide L, Nillius SJ. Increased bone turnover during gonadotropin-releasing hormone superagonist induced ovulation inhibition. J Clin Endocrinol Metab 1987;65:159–63.

    Google Scholar 

  4. Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J, Christiansen C. The effect of a gonadrotropin-releasing hormone agonist analog (Nafarelin) on bone metabolism. J Clin Endocrinol Metab 1987;67:701–6.

    Google Scholar 

  5. Matta WH, Shaw RW, Hesp R, Evans R. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrinol 1988;29:45–51.

    Google Scholar 

  6. Bianchi G, Costantini S, Anserini P, et al. Effects of gonadotrophin-releasing hormone agonist on uterine fibroids and bone density. Maturitas 1989;11:179–85.

    Google Scholar 

  7. Dawood MY, Lewis V, Ramos J. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol. Fertil Steril 1989;52:21–6.

    Google Scholar 

  8. Scharla SH, Minne HW, Waibel-Treber S, et al. Bone mass reduction after estrogen deprivation by long-acting ganadotrophin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1990;70:1055–61.

    Google Scholar 

  9. Devogelaer JP, Nagant de Deuxchaisnes C, Donnez J. Action of the luteinizing hormone releasing hormone agonists on bone mineral density. In: Brosens I, Donnez J, editors. The current status of endometriosis: research and management. Proceedings of the 3rd World Congress on Endometriosis, Brussels, June 1992. New York: Parthenon Publishing, 1993:345–68.

    Google Scholar 

  10. Devogelaer JP, Nagant de Deuxchaines C, Clerckx F, Donnez J. Effect of goserelin implants, an LHRH analogue, on lumbar and hip BMD, as studied by the DEXA technique. Calcif Tissue Int 1991;48(Suppl):298.

    Google Scholar 

  11. Cann CE, Henzl M, Burry K et al. Reversible bone loss is produced by the GnRH agonist nafarelin. In: Cohn DV, Martin TJ, Meunier PJ, editors. Calcium regulation and bone metabolism: basic and clinical aspects, vol 9. Amsterdam: Excerpta Medica, 1987:123–7.

    Google Scholar 

  12. Whitehouse RW, Adams JE, Baucroff K, Vaughan-Williams CA, Elstein M. The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clin Endocrinol 1990;33:365–73.

    Google Scholar 

  13. Riis BJ, Christiansen C, Johansen JS, Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 1990; 70:920–24.

    Google Scholar 

  14. Surrey ES, Judd HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and longacting gonadotropin releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab 1992;75:558–63.

    Google Scholar 

  15. Friedman AJ, Daly M, Juneau-Norcross M, et al. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin ‘add-back’ regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 1993;76:1439–45.

    Google Scholar 

  16. Reginster JY, Jeugmans-Huynen AM, Albert A, Denis D, Franchimont P. One year's treatment of Paget's disease of bone by synthetic salmon calcitonin as a nasal spray. J Bone Miner Res 1988;3:249–52.

    Google Scholar 

  17. Reginster JY, Denis D, Albert A, et al. One year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987;2:1481–3.

    Google Scholar 

  18. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose response study. BMJ 1992;305:61.

    Google Scholar 

  19. Reginster JY, Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 1985;3:155–7.

    Google Scholar 

  20. Roux C, Listrat V, Fechtenbaum J, et al. Bone mineral density of the proximal femur measured by dual energy X-ray absorptiometry. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Third International Symposium on Osteoporosis. Copenhagen: Osteopress, 1990:906–8.

    Google Scholar 

  21. Roux C, Listrat V, Poiraudeau S, Dougados M, Amor B. Measurement of the bone density of the wrist by dual energy X-ray absorptiometry. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Third International Symposium on Osteoporosis. Copenhagen: Osteopress, 1990:903–5.

    Google Scholar 

  22. Comite F, Delman M, Hutchinson-Williams K, Decherney AH, Jensen P. Reduced bone mass in reproductive aged women with endometriosis. J Clin Endocrinol Metab 1989;69:837–42.

    Google Scholar 

  23. Lane N, Baptista J, Snow-Harter C. Bone mineral density of the lumbar spine in endometriosis subjects compared to an age similar control population. J Clin Endocrinol Metab 1991;72:510–4.

    Google Scholar 

  24. Valente M, Primiero FM, Galoppi P, et al. Salmon calcitonin and bone turnover under GnRH analogue treatment. In: Christiansen C, Overgaard K, editors. Osteoporosis 1990. Third International Symposium on Osteoporosis. Copenhagen: Osteopress, 1990;1426–9.

    Google Scholar 

  25. Devogelaer JP, Nagant de Deuxchaisnes C, Lecart C, Donnez J, Thomas K. Inefficacy of the 50 units nasal spray of salmon calcitonin in patients after oophorectomy. J Bone Miner Res 1988;3(Suppl. 1):S162.

    Google Scholar 

  26. Mazzuoli GF, Tabolli S, Bigi F, et al. Effects of salmon calcitonin on the bone loss induced by ovariectomy Calcif Tissue Int 1990;47:209–14.

    Google Scholar 

  27. Ribot C, Tremollieres F, Pouilles JM, Chaumet-Riffaud P. Long term effect of nasal calcitonin on vertebral and femoral bone mass in early menopause: results of a controlled prospective 3-year study. J Bone Miner Res 1992; 7 (Suppl 1):415.

    Google Scholar 

  28. Pouilles JM, Tremollières F, Ribot C. The effects of menopause on longitudinal bone loss from the spine. Calcif Tissue Int 1993;52:340–3.

    Google Scholar 

  29. Field CS, Ory SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL. Preventive effects of trandermal 17β-estradiol on osteoporotic changes after surgical menopause: a two year placebo controlled trial. Am J Obstet Gynecol 1993;168:114–21.

    Google Scholar 

  30. Bickerstaff DR, Kanis JA. The use of nasal cacitonin in the treatment of post-traumatic algodystrophy. Br J Rheum 1991;30:291–4.

    Google Scholar 

  31. Dawood MY. Impact of medical treatment of endometriosis on bone mass. Am J Obstet Gynecol 1993;168:674–84.

    Google Scholar 

  32. Rico H, Arnanz F, Revilla M, et al. Total and regional bone mineral content in women treated with GnRH agonists. Calcif Tissue Int 1993;52:354–7.

    Google Scholar 

  33. Pascual E, Giner V, Arostegui A, Conill J, Ruiz MT, Pico A. Higher incidence of carpal tunnel syndrome in oophorectomized women. Br J Rheum 1991;31:60–2.

    Google Scholar 

  34. Friedman AJ, Juneau-Norcross M, Rein MS. Adverse effects of leuprolide acetate depot treatment. Fertil Steril 1993;59:448–50.

    Google Scholar 

  35. Chander CL, Spector TD. Oestrogens, joint disease, and cartilage. Ann Rheum Dis 1991;50:139–40.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinique de Rhumatologie, Hôpital Cochin, Université René Descartes, 27 rue du Faubourg Saint Jacques, F-75014, Paris, France

    C. Roux MD, V. Listrat, S. Kolta, M. Dougados & B. Amor

  2. AMGOP, Paris, France

    C. Pelissier

  3. Sandoz Recherche et Développement, France

    C. Simonetta & M. Guignard

Authors
  1. C. Roux MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Pelissier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Listrat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Kolta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Simonetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Guignard
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Dougados
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B. Amor
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roux, C., Pelissier, C., Listrat, V. et al. Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporosis Int 5, 185–190 (1995). https://doi.org/10.1007/BF02106098

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02106098

Keywords

Search

Navigation